Cannapharmarx (Cannapharmarx) EPS (Basic) : $-0.04 (TTM As of Sep. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx EPS (Basic)?

Cannapharmarx's basic earnings per share (Basic EPS) for the three months ended in Sep. 2023 was $-0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.04.

Cannapharmarx's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.04.

Cannapharmarx's EPS without NRI for the three months ended in Sep. 2023 was $-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was -0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cannapharmarx EPS (Basic) Historical Data

The historical data trend for Cannapharmarx's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannapharmarx EPS (Basic) Chart

Cannapharmarx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

-0.17

-0.66

-0.49

-0.12

-0.04

Cannapharmarx Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-0.02	-0.01	-0.01	-

Cannapharmarx EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cannapharmarx's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.531	-	0)	/	211.044
	=	-0.04

Cannapharmarx's Basic EPS for the quarter that ended in Sep. 2023 is calculated as

Basic EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.564	-	0)	/	295.096
	=	-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

Cannapharmarx (OTCPK:CPMD) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cannapharmarx EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannapharmarx (Cannapharmarx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 3rd Street SW, Suite 3600, Calgary, AB, CAN, T2P 5C5

Website

https://www.cannapharmarx.com

Cannapharmarx Inc is involved in the cannabis sector. The company negotiates, acquires, and develops various cannabis cultivation projects throughout Canada. Its three projects include the Hanover Project; the Great Northern Project; and the Acquisition of Sunniva Medical.

Executives

Anthony Michael Panek	director	95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin	director, officer: Chief Executive Officer	C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels	officer: Chief Financial Officer	SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman	director	302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman	officer: Chief Operating Officer	1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson	director	977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick	10 percent owner	7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson	director	PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia	director, 10 percent owner	2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess	director	2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood	director	P.O. BOX 4375, DILLON CO 80435
James E Smeeding	director	4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife	director	9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule	director	C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920